MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2023010349

Медицинская библиотека · Blood advances · 2023

Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.

Meejun Tanaporn, Srisurapanont Karan, Manothummetha Kasama, Thongkam Achitpol, Mejun Nuthchaya, Chuleerarux Nipat, Sanguankeo Anawin, Phongkhun Kasidis, Leksuwankun Surachai, Thanakitcharu Jaedvara, Lerttiendamrong Bhoowit, Langsiri Nattapong, Torvorapanit Pattama, Worasilchai Navaporn, Plongla Rongpong, Hirankarn Nattiya, Nematollahi Saman, Permpalung Nitipong, Moonla Chatphatai, Kates Olivia S

МетаанализСтатьяПеревод пока не подготовлен

Аннотация

Immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is diminished in hematopoietic stem cell transplant (HSCT) recipients. To summarize current evidence and identify risk factors for attenuated responses, 5 electronic databases were searched since database inceptions through 12 January 2023 for studies reporting humoral and/or cellular immunogenicity of SARS-CoV-2 vaccination in the HSCT population. Using descriptive statistics and random-effects models, extracted numbers of responders and pooled odds ratios (pORs) with 95% confidence intervals (CIs) for risk factors of negative immune responses were analyzed (PROSPERO: CRD42021277109). From 61 studies with 5906 HSCT recipients, after 1, 2, and 3 doses of messenger RNA (mRNA) SARS-CoV-2 vaccines, the mean antispike antibody seropositivity rates (95% CI) were 38% (19-62), 81% (77-84), and 80% (75-84); neutralizing antibody seropositivity rates were 52% (40-64), 71% (54-83), and 78% (61-89); and cellular immune response rates were 52% (39-64), 66% (51-79), and 72% (52-86). After 2 vaccine doses, risk factors (pOR; 95% CI) associated with antispike seronegativity were male recipients (0.63; 0.49-0.83), recent rituximab exposure (0.09; 0.03-0.21), haploidentical allografts (0.46; 0.22-0.95), <24 months from HSCT (0.25; 0.07-0.89), lymphopenia (0.18; 0.13-0.24), hypogammaglobulinemia (0.23; 0.10-0.55), concomitant chemotherapy (0.48; 0.29-0.78) and immunosuppression (0.18; 0.13-0.25). Complete remission of underlying hematologic malignancy (2.55; 1.05-6.17) and myeloablative conditioning (1.72; 1.30-2.28) compared with reduced-intensity conditioning were associated with antispike seropositivity. Ongoing immunosuppression (0.31; 0.10-0.99) was associated with poor cellular immunogenicity. In conclusion, attenuated humoral and cellular immune responses to mRNA SARS-CoV-2 vaccination are associated with several risk factors among HSCT recipients. Optimizing individualized vaccination and developing alternative COVID-19 prevention strategies are warranted.

Для цитирования: Meejun Tanaporn, Srisurapanont Karan, Manothummetha Kasama, Thongkam Achitpol, Mejun Nuthchaya, Chuleerarux Nipat, Sanguankeo Anawin, Phongkhun Kasidis, Leksuwankun Surachai, Thanakitcharu Jaedvara, Lerttiendamrong Bhoowit, Langsiri Nattapong, Torvorapanit Pattama, Worasilchai Navaporn, Plongla Rongpong, Hirankarn Nattiya, Nematollahi Saman, Permpalung Nitipong, Moonla Chatphatai, Kates Olivia S. Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2023010349.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.